With the market projected to grow in the coming years, driven by the increasing prevalence of these conditions, pharmaceutical companies have been investing heavily in developing and marketing GLP-1 agonists
Despite these benefits, weight loss from GLP-1 agonists often results in overall fat reduction, including areas where patients might want to retain volume
10.1016/j.numecd.2016.01.011 32
Otherwise, when the bottle is opened, water will enter, and the stability will decrease
Stacking two GLP-1 class compounds (e.g., semaglutide + tirzepatide) is not supported by any clinical trial, is likely to produce additive GI side effects, and has no mechanistic rationale the receptors overlap too much
For sterile injectable medications, pharmacies typically follow internal protocols designed to reduce contamination risk and help support consistency from batch to batch